Yong Ai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yong Ai Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Junbo Wu
Changzhi People’s Hospital Affiliated to Changzhi Medical College
2 shared publicationsLi Ma
Changzhi Medical College
2 shared publicationsWenqing Hu
Changzhi People’s Hospital Affiliated to Changzhi Medical College
2 shared publicationsFeng Hua Ma
Department of Radiology, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China
1 shared publicationGuo Fu Zhang
Department of Radiology, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China
1 shared publication- Jin Wei Qiang
Department of Radiology, Jinshan Hospital of Fudan University, Shanghai, China
1 shared publication
Latest Publications
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e250345
Multiparametric MRI–based Deep Learning and Radiomics for Evaluating Lymph Node Metastasis in Early-Stage Cervical Cancer
Radiomics and deep learning–radiomics fusion models constructed using tumor and pelvic lymph node features from MRI demonstrated favorable performance for preoperative lymph node metastasis prediction in early-stage cervical cancer.
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e250345
Multiparametric MRI–based Deep Learning and Radiomics for Evaluating Lymph Node Metastasis in Early-Stage Cervical Cancer
Radiomics and deep learning–radiomics fusion models constructed using tumor and pelvic lymph node features from MRI demonstrated favorable performance for preoperative lymph node metastasis prediction in early-stage cervical cancer.
- Open Access
- 22 January 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2610907
Development and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs), ranging from mild to life-threatening. High-risk irAEs can lead to treatment discontinuation and higher mortality, though ICI-treated patients' death rate is under 5%. Currently, no reliable biomarkers predict irAEs' occurrence or severity. This study investigates the link between accessible biomarkers and high-risk irAEs in gastric cancer patients on ICIs, as well as to develop and assess a predictive model for such events. Data were collected from patients with gastric cancer who received ICIs therapy between May 2020 and March 2025. The incidence and risk factors associated with irAEs were analyzed using the chi-square test or the Mann-Whitney U test. Univariate and multivariate logistic regression analyses were conducted to develop a predictive model. This model was validated through 10-fold cross-validation and assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), calibration curves, and decision curve analysis. A total of 184 gastric cancer patients receiving ICIs therapy were enrolled in this study. The incidence of irAEs of any grade was 21.2%, while the incidence of grade ≥3 irAEs was 12.5%. Multivariate logistic regression analysis identified NLR-1 (p < .001), NLR2-1 (p < .001), PLR-1 (p = .001), tumor thickness (p = .018), CV (p = .001), and intratumoral necrosis (p = .028) as independent predictors of grade ≥3 irAEs. The AUC of the developed model was 0.878, with a sensitivity of 78.26%, specificity of 80.12%, PPV of approximately 80.95%, and NPV of approximately 75.52%. The corrected C-index, derived from bootstrap resampling, was 0.849, and both calibration curves and decision curve analysis confirmed good calibration and clinical utility. These predictors may aid risk stratification and optimized patient management.
- 22 January 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2610907
Open AccessDevelopment and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs), ranging from mild to life-threatening. High-risk irAEs can lead to treatment discontinuation and higher mortality, though ICI-treated patients' death rate is under 5%. Currently, no reliable biomarkers predict irAEs' occurrence or severity. This study investigates the link between accessible biomarkers and high-risk irAEs in gastric cancer patients on ICIs, as well as to develop and assess a predictive model for such events. Data were collected from patients with gastric cancer who received ICIs therapy between May 2020 and March 2025. The incidence and risk factors associated with irAEs were analyzed using the chi-square test or the Mann-Whitney U test. Univariate and multivariate logistic regression analyses were conducted to develop a predictive model. This model was validated through 10-fold cross-validation and assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), calibration curves, and decision curve analysis. A total of 184 gastric cancer patients receiving ICIs therapy were enrolled in this study. The incidence of irAEs of any grade was 21.2%, while the incidence of grade ≥3 irAEs was 12.5%. Multivariate logistic regression analysis identified NLR-1 (p < .001), NLR2-1 (p < .001), PLR-1 (p = .001), tumor thickness (p = .018), CV (p = .001), and intratumoral necrosis (p = .028) as independent predictors of grade ≥3 irAEs. The AUC of the developed model was 0.878, with a sensitivity of 78.26%, specificity of 80.12%, PPV of approximately 80.95%, and NPV of approximately 75.52%. The corrected C-index, derived from bootstrap resampling, was 0.849, and both calibration curves and decision curve analysis confirmed good calibration and clinical utility. These predictors may aid risk stratification and optimized patient management.
- 11 December 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 109, 103907
CIA-net: Cross-modality interaction and aggregation network for ovarian tumor segmentation from multi-modal MRI
- 11 December 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 109, 103907
CIA-net: Cross-modality interaction and aggregation network for ovarian tumor segmentation from multi-modal MRI
- Open Access
- 1 September 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Prediction of Occult Peritoneal Metastasis of Gastric Cancer Based on CT-Based Body Fat Analysis
Introduction: We aimed to investigate the predictive value of body fat composition parameters obtained using computed tomography (CT) for preoperative occult peritoneal metastasis (OPM) in gastric cancer. Methods: We adopted a single-center case-control design and retrospectively analyzed data from 115 patients with gastric cancer who underwent laparoscopic exploration or radical gastrectomy at our hospital between October 2020 and March 2024. Patients were divided into OPM-positive (n = 35) and OPM-negative (n = 80) groups. The visceral adipose tissue (VAT) area, subcutaneous adipose tissue (SAT) area, and mean attenuation of CT images at the central level of the L3 lumbar spine were measured using the sliceOmatic software, and the clinical and imaging characteristics of the patients were analyzed. Results: Significant differences were present in the VAT area, VAT/SAT area, mean attenuation of SAT, mean attenuation of VAT, VAT area of different N stages, and lesion sites between the OPM-positive and OPM-negative groups ( P < 0.05). Results of a multifactor logistic regression analysis showed that the VAT/SAT area ratio and VAT mean attenuation were independent risk factors for OPM in gastric cancer ( P < 0.05). The AUC of the clinical-imaging model in predicting gastric cancer OPM was 0.92 (95% confidence interval, 0.86-0.97). A VAT/SAT area of 1.04 (specificity: 54%, sensitivity: 86%) and a VAT mean attenuation of −83.60 Hounsfield unit (HU) (specificity: 99%, sensitivity:34%) were used as optimal cutoff values for identifying the occurrence of OPM in gastric cancer. Conclusion: VAT/SAT area ratio and mean VAT attenuation in body fat composition are potential auxiliary parameters for predicting OPM in gastric cancer.
- 1 September 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Open AccessPrediction of Occult Peritoneal Metastasis of Gastric Cancer Based on CT-Based Body Fat Analysis
Introduction: We aimed to investigate the predictive value of body fat composition parameters obtained using computed tomography (CT) for preoperative occult peritoneal metastasis (OPM) in gastric cancer. Methods: We adopted a single-center case-control design and retrospectively analyzed data from 115 patients with gastric cancer who underwent laparoscopic exploration or radical gastrectomy at our hospital between October 2020 and March 2024. Patients were divided into OPM-positive (n = 35) and OPM-negative (n = 80) groups. The visceral adipose tissue (VAT) area, subcutaneous adipose tissue (SAT) area, and mean attenuation of CT images at the central level of the L3 lumbar spine were measured using the sliceOmatic software, and the clinical and imaging characteristics of the patients were analyzed. Results: Significant differences were present in the VAT area, VAT/SAT area, mean attenuation of SAT, mean attenuation of VAT, VAT area of different N stages, and lesion sites between the OPM-positive and OPM-negative groups ( P < 0.05). Results of a multifactor logistic regression analysis showed that the VAT/SAT area ratio and VAT mean attenuation were independent risk factors for OPM in gastric cancer ( P < 0.05). The AUC of the clinical-imaging model in predicting gastric cancer OPM was 0.92 (95% confidence interval, 0.86-0.97). A VAT/SAT area of 1.04 (specificity: 54%, sensitivity: 86%) and a VAT mean attenuation of −83.60 Hounsfield unit (HU) (specificity: 99%, sensitivity:34%) were used as optimal cutoff values for identifying the occurrence of OPM in gastric cancer. Conclusion: VAT/SAT area ratio and mean VAT attenuation in body fat composition are potential auxiliary parameters for predicting OPM in gastric cancer.